[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Cyclin Dependent Kinase 2 - Pipeline Review, H2 2019

December 2019 | 82 pages | ID: C4EF7BED63FCEN
Global Markets Direct

US$ 3,500.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
Cyclin Dependent Kinase 2 - Pipeline Review, H2 2019

SUMMARY

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) pipeline Target constitutes close to 16 molecules. Out of which approximately 13 molecules are developed by companies and remaining by the universities/institutes. The latest report Cyclin Dependent Kinase 2 - Pipeline Review, H2 2019, outlays comprehensive information on the Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Cyclin-dependent kinase 2 is an enzyme encoded by the CDK2 gene. CDK2 is the catalytic subunit of the cyclin-dependent protein kinase complex which regulates progression through the cell cycle. Activity of CDK2 is especially critical during the G1 to S phase transition. CDK2 associates with and regulated by other subunits of the complex including cyclin A or E, CDK inhibitor p21Cip1 (CDKN1A), and p27Kip1 (CDKN1B). The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 1, 4 and 2 respectively.

Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 2 molecules, respectively. Report covers products from therapy areas Oncology, Ear Nose Throat Disorders, Immunology, Infectious Disease, Metabolic Disorders and Respiratory which include indications Breast Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Neuroblastoma, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Chronic Lymphocytic Leukemia (CLL), Solid Tumor, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Anaplastic Astrocytoma, Colon Cancer, Cystic Fibrosis, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Glioblastoma Multiforme (GBM), Gliosarcoma, Hearing Disorders, Laryngeal Cancer, Mantle Cell Lymphoma, Metastatic Hepatocellular Carcinoma (HCC), Multiple Myeloma (Kahler Disease), Myelodysplastic Syndrome, Non-Small Cell Lung Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Peritoneal Cancer, Pituitary ACTH Hypersecretion (Cushing Disease), Pseudomonas aeruginosa Infections, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Rheumatoid Arthritis, Thymic Carcinoma, Triple-Negative Breast Cancer (TNBC) and Uterine Cancer.

Furthermore, this report also reviews key players involved in Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)
  • The report reviews Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) targeted therapeutics
REASONS TO BUY
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Overview
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Companies Involved in Therapeutics Development
Adastra Pharmaceuticals Inc
Apollo Therapeutics LLC
Astex Pharmaceuticals Inc
Cyclacel Pharmaceuticals Inc
G1 Therapeutics Inc
Neosome Life Sciences LLC
Pfizer Inc
Prous Institute for Biomedical Research SA
Rizen (Suzhou) Biosciences Co Ltd
Tiziana Life Sciences Plc
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Drug Profiles
AT-7519 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CCT-68127 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CYC-065 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JRP-890 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JS-104 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
kenpaullone - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
milciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NEOS-518 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-06873600 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sapacitabine + seliciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
seliciclib - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit CDK2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDK2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDK2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit CDK2 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zotiraciclib citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Dormant Products
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Discontinued Products
Cyclin Dependent Kinase 2 (p33 Protein Kinase or Cell Division Protein Kinase 2 or CDK2 or EC 2.7.11.22) - Product Development Milestones
Featured News & Press Releases
Dec 09, 2019: Cyclacel’s CYC065 and Venetoclax demonstrate therapeutic potential and anticancer activity in acute myeloid and chronic lymphocytic leukemias
Nov 06, 2019: Cyclacel Pharmaceuticals announces multiple clinical abstracts on CYC065 selected for presentation at the ASH 2019 Annual Meeting
Sep 09, 2019: Cyclacel Pharmaceuticals announces first patient treated with oral CYC065 in a phase 1 study in patients with advanced solid tumors
Sep 04, 2019: Tiziana Life Sciences -phase 2a clinical data
Sep 04, 2019: Adastra Pharmaceuticals to present at the 2019 Janney Healthcare Conference
Jul 24, 2019: Tiziana reveals positive results for Milciclib in liver cancer trial
Jul 22, 2019: Tiziana reports phase 2a clinical data with milciclib monotherapy in Sorafenib-refractory or -intolerant patients with unresectable or metastatic Hepatocellular Carcinoma
Jun 03, 2019: Adastra Pharmaceuticals announces positive interim data from Phase 1b clinical trial of zotiraciclib in the treatment of recurrent malignant gliomas
May 16, 2019: Adastra Pharmaceuticals announces that data from phase 1b clinical trial of Zotiraciclib will be presented at ASCO 2019
Apr 24, 2019: Tiziana reports encouraging interim clinical data from an ongoing phase 2a trial with milciclib in advanced liver cancer patients
Mar 25, 2019: Cyclacel: Publication identifies cyclin e as key resistance pathway to Breast Cancer treated by CDK4/6 inhibitors and thereby amenable to treatment by CYC065 CDK2/9 inhibitor
Mar 05, 2019: Cyclacel announces CYC065 abstract presentation at the American Association for Cancer Research Annual Meeting 2019
Dec 03, 2018: Tiziana Completes patient enrollment in a phase 2a trial to evaluate tolerability and anti-tumor activity of Milciclib in hepatocellular carcinoma (HCC)
Oct 16, 2018: Tiziana Life Sciences presents data from animal studies demonstrating the potential synergistic activity of Milciclib with tyrosine kinase inhibitors to treat Hepatocellular Carcinoma (HCC) at the American Association for the Study of Liver Diseases (AASLD)
Jun 14, 2018: Lees Pharmaceutical Holdings: Update on An Investigational Oncology Product
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indications, H2 2019
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Adastra Pharmaceuticals Inc, H2 2019
Pipeline by Apollo Therapeutics LLC, H2 2019
Pipeline by Astex Pharmaceuticals Inc, H2 2019
Pipeline by Cyclacel Pharmaceuticals Inc, H2 2019
Pipeline by G1 Therapeutics Inc, H2 2019
Pipeline by Neosome Life Sciences LLC, H2 2019
Pipeline by Pfizer Inc, H2 2019
Pipeline by Prous Institute for Biomedical Research SA, H2 2019
Pipeline by Rizen (Suzhou) Biosciences Co Ltd, H2 2019
Pipeline by Tiziana Life Sciences Plc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Dormant Products, H2 2019 (Contd..2), H2 2019
Discontinued Products, H2 2019

LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019

COMPANIES MENTIONED

Adastra Pharmaceuticals Inc
Apollo Therapeutics LLC
Astex Pharmaceuticals Inc
Cyclacel Pharmaceuticals Inc
G1 Therapeutics Inc
Neosome Life Sciences LLC
Pfizer Inc
Prous Institute for Biomedical Research SA
Rizen (Suzhou) Biosciences Co Ltd
Tiziana Life Sciences Plc


More Publications